recombinant hnoggin (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
96
Structured Review
R&D Systems
recombinant hnoggin
Recombinant Hnoggin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 268 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnoggin/Recombinant+Human+Noggin+Protein/pmc12314152__deaf113_supplementary_table_s2-1-104-109
Average 96 stars, based on 268 article reviews
Recombinant Hnoggin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 268 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hnoggin/Recombinant+Human+Noggin+Protein/pmc12314152__deaf113_supplementary_table_s2-1-104-109
Average 96 stars, based on 268 article reviews
recombinant hnoggin - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
other:Article Title: Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Article Snippet: The following components were used: 50 ng Article Title: Expansion of ventral foregut is linked to changes in the enhancer landscape for organ-specific differentiation. Article Snippet: Day-5 expanding VFG cells were used for pancreatic differentiations under hypoxic conditions (5% O2/5% CO2/37 °C) according to protocols described as below: For the protocol adapted from Ameri et al.22, day-5 expanding VFG cells were treated with DMEM high-glucose GlutaMAX Supplement with 1% vol/vol B27 supplement as basal medium throughout the differentiation and were supplemented with 2 μM RA (Sigma-Aldrich, R2625) for 3 days; then with 64 ng ml−1 FGF2 and 50 ng ml−1 Article Title: nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Article Snippet: Human PDO#2 line was grown in DMEM/F12 [+] L-Glutamine [+] 2.438 g/L sodium bicarbonate (Gibco, 11320-033) supplemented with 1X Penicillin/Streptomycin (Corning, 30-002-Cl), 10mM HEPES (Gibco, 15630-080), 1.25mM N-Acetylcysteine (Sigma-Aldrich, A9165), 10mM Nicotinamide (Sigma-Aldrich, N0636), 100ug/mL Primocin (InvivoGen, ant-pm-05), 1X NeuroCultTM SM1 Neuronal Supplement (Stem Cells Technology, 05711), 50ng/mL Article Title: Nodal signaling is required for mesodermal and ventral but not for dorsal fates in the indirect developing hemichordate, Ptychodera flava Article Snippet: The reagents used were: mNodal (#1315-ND), hNodal (#3218-ND), mLefty (#994-LF), zBmp4 (#1128-BM), mBmp4 (#5020-BP) and Article Title: Antibodies binding to BMP4, and uses thereof Article Snippet: After overnight attachment cells were stimulated with 10 ng/ml Article Title: Expansion of ventral foregut is linked to changes in the enhancer landscape for organ-specific differentiation Article Snippet: Day-5 expanding VFG cells were used for pancreatic differentiations under hypoxic conditions (5% O 2 /5% CO 2 /37 °C) according to protocols described as below: For the protocol adapted from Ameri et al. , day-5 expanding VFG cells were treated with DMEM high-glucose GlutaMAX Supplement with 1% vol/vol B27 supplement as basal medium throughout the differentiation and were supplemented with 2 μM RA (Sigma-Aldrich, R2625) for 3 days; then with 64 ng ml −1 FGF2 and 50 ng ml −1 Article Title: Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma Article Snippet: The following components were used: 50 ng Concentration Assay:Article Title: Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors Article Snippet: To analyze VHH specificity, C2C12 cells were stimulated with 10 ng/ml of hBMP4 (Cat. No. 314-BP-020; R&D Systems), 50 ng/ml of hBMP2 (Cat. No. 355-BM-010; R&D Systems), 200 ng/ml of hBMP5 (Cat. No. 615-BMC-020; R&D Systems), 50 ng/ml of hBMP6 (Cat. No. 506-BP-020; R&D Systems), 200 ng/ml of hBMP7 (Cat. No. 354-BP-010; R&D Systems), 25 ng/ml of hBMP9 (Cat. No. 3209-BP-010; R&D Systems), 25 ng/ml of hBMP10 (Cat. No. 2926-BP-025; R&D Systems), and 50 ng/ml of hBMP12 (Cat. No. 779-G7-010; R&D Systems). .. At the same time, different inhibitors were added: C4C4 and C8C8 at a concentration of 500 ng/ml; |
